CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
Evan
E
Wood
Robert S
RS
Hogg
Benita
B
Yip
Michael V
MV
O'Shaughnessy
Julio S G
JS
Montaner
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine